180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has announced that adalimumab, its anti-TNF treatment, has shown potential to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease. According to the announcement, researchers at Oxford Population Health’s Health Economics Research Centre and the Kennedy Institute of Rheumatology have identified the potential; adalimumab is commonly used to treat conditions such as rheumatoid arthritis and psoriasis. Currently, there is no approved treatment for early-stage Dupuytren’s disease, which causes the fingers to irreversibly curl into the palm due to nodules of tissue forming cords under the skin, impairing hand function and quality of life. The new research is the result of a recent phase 2b trial led by Professor Jagdeep Nanchahal of the Kennedy Institute of Rheumatology, University of Oxford; Nanchahal is also a consultant to ATNF. The company noted that the trial found that a course of four adalimumab injections significantly reduced hardness and size of early-stage Dupuytren’s disease nodules. “Determining that adalimumab is likely to be cost effective for early-stage Dupuytren’s disease is an important step towards working to successfully bring the treatment to market and making it widely available to patients,” said 180 Life Sciences CEO Dr. James Woody in the press release. “This, combined with our extensive patent estate, has provided strong interest in ongoing preliminary partnership discussions for the commercialization of this novel therapeutic approach.”

To view the full press release, visit https://ibn.fm/K6NNH

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company driving groundbreaking studies into clinical programs that are seeking to address major unmet medical needs. The company’s primary platform is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.